TKNO Q3 2023 Earnings — Alpha Teknova, Inc. Revenue & Financial Results | Market Cap Arena

TKNOAlpha Teknova, Inc.

$133M

Q3 2023 Earnings

Healthcare Drug Manufacturers - Specialty & Generic

Income Statement

Revenue

$8M-23.6% YoY

Gross Profit

$1M18.0% margin

Operating Income

-$9M-107.3% margin

Net Income

-$10M-124.3% margin

EPS (Diluted)

$-0.34

QoQ Revenue Growth

-29.1%

Cash Flow

Operating Cash Flow

-$4M

Free Cash Flow

-$5M

Stock-Based Comp.

$0

Balance Sheet

Total Assets

$138M

Total Liabilities

$39M

Stockholders' Equity

$100M

Cash & Equivalents

$32M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$11M	-23.6%
Gross Profit	$1M	$5M	-69.1%
Operating Income	-$9M	-$23M	+61.8%
Net Income	-$10M	-$22M	+54.8%

Revenue Segments

Lab Essentials

$7M89%

Clinical Solutions

$597,0007%

Other Product

$298,0004%

Geographic Segments

UNITED STATES

$8M96%

Non-US

$342,0004%